US EditionCancer Survivor Turned Pro Pickleball Player
La Paz University Hospital's tandem CAR-T therapy targets two leukemia proteins, achieving over 70% survival in patients under 24 with no other treatment options.
- On Thursday, pediatrician Antonio Pérez presented results at La Paz University Hospital showing a 70% survival rate after more than a year and a half of follow-up, with eight young people saved by the living drug.
- Patients under the age of 24 had been declared terminal after multiple relapses and failure of all conventional treatments, prompting experimental approaches as Spain records about 1,500 childhood cancer cases annually and Pérez says public hospitals must lead development.
- The treatment extracts immune cells, re-engineers them with 'tandem' CAR-T binding CD19 and CD22, making cancer undetectable in eight of 11 patients within a month, with five receiving transplants.
- Recovered children returned to normal life, exemplified by a delighted 15-year-old patient Lucía Álvarez who joined doctors, politicians, and donors at the presentation.
- Over the past year, the Barcelona academic CAR-T cost 90,000, demonstrating that public hospitals can develop affordable therapies and collaborate across the EU, which has approved eight CAR-T products.
18 Articles
18 Articles
A living drug that fits on a spoon saves the lives of eight young people with the most common childhood cancer
A new living drug, made up of cells small enough to fit on a spoon and produced at a public hospital in Madrid, has so far saved the lives of eight young people suffering from an extremely aggressive form of the most common childhood cancer — B-cell acute lymphoblastic leukemia. The patients, all under the age of 24, had been declared terminal after multiple relapses and the failure of all conventional treatments.Seguir leyendo
To remove white blood cells from the patient, send them to the laboratory to modify them and use them as a tool for the body itself to destroy malignant cells. After this, a bone marrow transplant is carried out. This procedure called CAR-T Tandem or Dual therapy is used by the La Paz hospital to cure seven young people who had advanced leukemia and had undergone other treatments. This is the case of Lucia, who has lived with this disease 14 yea…
«Right now I am fine. This treatment has returned my faith because after so much admission I thought there was no cure» . The one who speaks, with a nervous voice, is Lucía Álvarez, 15 years old, who since she is 17 months old has struggled with intermittent leukemia, which has reappeared up to four times, after receiving the conventional treatments.
elcorreogallego.es
lacronicabadajoz.comOn Thursday, the CRIS Anti-Cancer Foundation presented a hopeful study on pediatric type B acute lymphoblastic leukemia (LLA-B) in relapse or refractory led by Dr. Antonio Pérez Martínez, director of the CRIS Advanced Therapies in Childhood Cancer Unit located at the La Paz University Hospital in Madrid. The presentation of the study has counted on the children who have been part of this research together with their families.
The Cris Anticancer Foundation presents in La Paz Hospital in Madrid the hopeful results of applying CAR-T cells in tandem to patients with relapse and
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
